Arizona State University

Harvard College

Dana-Farber-Cancer Institute Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The Brigham and Women's Hospital, Inc.

Baylor College of Medicine

Icahn School of Medicine at Mount Sinai

Arizona Board of Regents, a Body Corporate

Recognition Analytix, Inc.

Karen Anderson

Joshua LaBaer

Garrick Wallstrom

Benjamin Katchman

Niroshan Ramachandran

Sahar Sibani

Sri Krishna

Joseph T Smith

Jin Park

Mo Reza Ebrahimkhani

Samira Kiani

Daniel Cramer

Farzaneh Moghadam

Jie Wang

Jennifer Blain Christen

Radwa Ewaisha

Jonine Figueroa

Shayesteh Roshdi Ferdosi

Stuart Lindsay

Jennifer M Blain Christen

Ji Qiu

Andrew Sikora

Marshall Posner

Ji Qui

Sepideh Afsari Mamaghani

Mark Knappenberger

Jacob L Swett

The present disclosure provides devices, systems, and methods related to single molecule detection. In particular, the present disclosure provides devices and methods for sequence-specific detection of a nucleic acid target using current fluctuations as a readout for protein binding to the nucleic acid target. As described herein, certain aspects of the bioelectronic devices and method can be used to detect and identify any nucleic acid target for the purpose of diagnosis and/or treatment.

Single-molecule electronic sequence detector and methods of use

Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Autoantibody biomarkers for the early detection of ovarian cancer

Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.

Modulating human Cas9-specific host immune response

Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).

Plasma autoantibody biomarkers for basal like breast cancer

Provided herein are methods of detecting and measuring disease-associated analytes such as proteins and antibodies in a sweat sample. Also provided are methods of determining and monitoring the disease state or physiological condition of a subject using small sweat samples.

Sweat as a biofluid for analysis and disease identification

The present invention provides reagents and methods for breast cancer detection.

Biomarkers for the early detection of breast cancer

A fully integrated miniaturized optical biosensor and methods of making the same are disclosed. The biosensor may include a fluid transport system and an optical system.

Flexible optical biosensor for point of use multi-pathogen detection

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

Materials and methods relating to immunogenic epitopes from human papillomavirus

Systems and methods for low-cost point-of-care immunoassay are provided. The system comprises an emitter, two optical interference filters, a microscope slide, a photodiode detector, a circuit, and a measuring unit. The detector is placed upon the second filter, the slide, the first filter, and then the emitter. The emitter comprises non-organic light emitting diodes (LEDs) or organic light emitting diodes (OLEDs) that emits light of a first color. The slide is spotted with biofluid from a patient. Biomarkers in the biofluid is bound with immobilized fluorophores that emit light of a second color when stimulated by the light of the first color. The first and second filters band-pass the light of the first and second colors, respectively. The detector detects light of the second color. The current outputted from the detector is converted into a relatively-large output voltage by a circuit. A measuring unit measures the ramp time of the output voltage. The ramp time is to be used to determine the concentration of the fluorophores, which in turn is related to the concentration of the biomarkers.

Point-of-care fluorescent immunoassay for identifying biomarkers in patient biofluid samples

Growing community of inventors

Scottsdale, AZ, United States of America

Karen Anderson